Kintara Therapeutics, Inc. (NASDAQ:KTRA) Short Interest Update

Kintara Therapeutics, Inc. (NASDAQ:KTRA) was the recipient of a significant growth in short interest in the month of July. As of July 31st, there was short interest totalling 1,720,000 shares, a growth of 74.9% from the July 15th total of 983,600 shares. Based on an average daily trading volume, of 11,060,000 shares, the short-interest ratio is presently 0.2 days.

Kintara Therapeutics Stock Up 1.6 %

Shares of KTRA traded up $0.00 during mid-day trading on Friday, reaching $0.19. 120,689 shares of the stock traded hands, compared to its average volume of 11,782,699. The firm has a market cap of $10.62 million, a price-to-earnings ratio of -0.05 and a beta of 0.93. The stock has a fifty day simple moving average of $0.24 and a 200 day simple moving average of $0.17. Kintara Therapeutics has a 12-month low of $0.08 and a 12-month high of $5.00.

Kintara Therapeutics (NASDAQ:KTRA) last posted its quarterly earnings data on Tuesday, May 14th. The company reported ($0.05) earnings per share (EPS) for the quarter.

About Kintara Therapeutics

Kintara Therapeutics, Inc, a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a late stage photodynamic therapy for the treatment of cutaneous metastatic breast cancer, basal cell carcinoma nevus syndrome, and access graft failure in hemodialysis patients.